Recurrence-free survival of stage 2 and 3 colon cancer patients managed with or without chemotherapy
Standing
Undergraduate
Type of Proposal
Poster Presentation
Faculty
Schulich School of Medicine Windsor
Faculty Sponsor
Akmal Ghafoor
Proposal
The benefits of chemotherapy are contested in stage 2 and 3 colon cancer. This retrospective study examined the recurrence-free survival of colon cancer patients treated with or without post-surgical chemotherapy. Data reviewed was of patients diagnosed with stage 2 or 3 colon cancer from 2013 to 2018 at a single center. Recurrence-free survival graphs of both stage 2 and stage 3 patients did not display a significant difference between the chemotherapy group versus the non-chemotherapy group. Recurrence-free survival at 3 years post-surgery was estimated to be 76% for stage 2 patients receiving chemotherapy versus 86% for stage 2 patients not receiving chemotherapy and 69% for stage 3 patients receiving chemotherapy versus 61% for stage 3 patients not receiving chemotherapy. This data indicates that chemotherapy does not predict survival outcomes based on disease stage alone. Notable survival differences at the 3-year mark, despite not being statistically significant, suggest that deeper analysis of chemotherapy regimen and patient profile may reveal factors that could improve clinical chemotherapy decisions.
Recurrence-free survival of stage 2 and 3 colon cancer patients managed with or without chemotherapy
The benefits of chemotherapy are contested in stage 2 and 3 colon cancer. This retrospective study examined the recurrence-free survival of colon cancer patients treated with or without post-surgical chemotherapy. Data reviewed was of patients diagnosed with stage 2 or 3 colon cancer from 2013 to 2018 at a single center. Recurrence-free survival graphs of both stage 2 and stage 3 patients did not display a significant difference between the chemotherapy group versus the non-chemotherapy group. Recurrence-free survival at 3 years post-surgery was estimated to be 76% for stage 2 patients receiving chemotherapy versus 86% for stage 2 patients not receiving chemotherapy and 69% for stage 3 patients receiving chemotherapy versus 61% for stage 3 patients not receiving chemotherapy. This data indicates that chemotherapy does not predict survival outcomes based on disease stage alone. Notable survival differences at the 3-year mark, despite not being statistically significant, suggest that deeper analysis of chemotherapy regimen and patient profile may reveal factors that could improve clinical chemotherapy decisions.
